Results 101 to 110 of about 67,273 (233)

Can Cytosine Arabinoside With Prednisolone Treatment for Canine Meningoencephalitis of Unknown Origin Increase Survival Time Compared to Prednisolone Treatment Alone?

Veterinary Evidence, 2018
PICO questionIn treatment of canine patients with meningoencephalitis of unknown origin (MUO), is combination therapy of cytosine arabinoside (CA) with prednisolone more effective than prednisolone as a sole therapy at increasing survival time?Clinical ...
Christopher Stefan Francis Kozlowski Hoey, Christina Maunder   +1 more
doaj   +1 more source

Improved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification

British Journal of Haematology, EarlyView.
Summary Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence‐based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)‐like regimen; an acute myeloid leukaemia (AML)‐like regimen;
Lisa‐Maj Christensen, Mikkel Runason Simonsen, Jonas Faartoft Jensen, Daniel Tuyet Kristensen, Karen Dybkær, Kirsten Grønbæk, Tarec Christoffer El‐Galaly, Marianne Schmidt Ettrup, Hans Beier Ommen, Anne Louise Tølbøll Sørensen, Dennis Lund Hansen, Marianne Tang Severinsen   +11 more
wiley   +1 more source

Recent Advances in Treatment of Primary Central Nervous System Lymphoma [PDF]

, 2014
Opinion statement Therapeutic options are limited in primary central nervous system lymphoma (PCNSL) with no uniform consensus on optimal management and few published, randomized trials.
Batchelor, Tracy T., Nayak, Lakshmi
core   +1 more source

Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH‐TC study

British Journal of Haematology, EarlyView.
Summary This prospective study evaluated the incidence and dynamics of frailty in 156 adults with lymphoproliferative syndromes undergoing autologous haematopoietic stem cell transplantation (HSCT). Frailty was assessed using the haematopoietic cell transplantation (HCT) frailty scale in patients from 15 Spanish institutions at initial consultation ...
Javier Cornago, Mónica Baile, Marina Acera, Laura Fox, María del Mar Pérez‐Artigas, Ana Santamaría, María del Carmen Quintela, Andrés Sánchez‐Salinas, Joaquina M. Salmerón, Verónica Illana, Zahra Abdallahi‐Lefdil, Laura Pardo, Laura Solán, José Luis López‐Lorenzo, Sara Fernández‐Luis, Leddy Patricia Vega, Sara Villar, Patricia Beorlegui‐Murillo, Mónica Molina, Albert Esquirol, Isabel Izquierdo, Julia Ribes, Alberto Mussetti, Esperanza Lavilla, Olga Alda, Javier López‐Marín, Leyre Bento, Silvia Filaferro, Pascual Balsalobre, Anna Sureda, María Queralt Salas   +30 more
wiley   +1 more source

Real‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom

British Journal of Haematology, EarlyView.
Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas, Gabriel Naylor‐Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J. Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N. Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C. P. Somervaille, Donal P. McLornan, on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group   +35 more
wiley   +1 more source

Comparison of Hospital Length of Stay and Supportive Care Utilization Between Patients Treated with CPX-351 and 7+3 for Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes

ClinicoEconomics and Outcomes Research, 2022
Kwanza Price,1 Zhun Cao,2 Craig Lipkin,2 Deb Profant,1 Scott Robinson2 1Jazz Pharmaceuticals, Palo Alto, CA, USA; 2Premier Inc., Charlotte, NC, USACorrespondence: Deb ProfantJazz Pharmaceuticals, 3170 Porter Dr., Palo Alto, CA, 94304, USATel/Fax +1 971 ...
Price K, Cao Z, Lipkin C, Profant D, Robinson S   +4 more
doaj  

Integrating Phase 2 into Phase 3 based on an Intermediate Endpoint While Accounting for a Cure Proportion -- with an Application to the Design of a Clinical Trial in Acute Myeloid Leukemia

, 2019
For a trial with primary endpoint overall survival for a molecule with curative potential, statistical methods that rely on the proportional hazards assumption may underestimate the power and the time to final analysis.
Heinzmann, Dominik, Monnet, Annabelle, Rufibach, Kaspar   +2 more
core   +1 more source

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

Cancer Science, EarlyView.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang   +15 more
wiley   +1 more source

Delivery of cytarabine by pegylated liposomes for efficient, long-term anticancer effects [PDF]

, 2014
The cytosine arabinoside cytarabine is an effective marine-derived antineoplastic agent for the treatment of acute myelogrnous and lymphocytic leukemias.
Borges, C., Cavaco-Paulo, Artur, Gomes, A. C., Guimarães, Diana Isabel Pereira, Matamá, Maria Teresa, Nogueira, Eugénia, Oliveira, A., Sárria, M. P.   +7 more
core  

The Natural Quassinoid Brusatol Enhances Venetoclax Efficacy and Overcomes Resistance in Myeloid Leukemias

Cancer Science, EarlyView.
Schematic illustration of the mechanisms by which the natural quassinoid brusatol induces apoptosis in myeloid leukemias and enhances venetoclax efficacy via p53‐dependent apoptosis and mitochondrial dysfunction. ABSTRACT While venetoclax‐based combinations have shown promising results in acute myeloid leukemia (AML), the remission duration is ...
Shin‐ichiro Kawaguchi, Kazuya Sato, Junko Izawa, Norihito Takayama, Hiroko Hayakawa, Ken Suzaki, Susumu Goyama, Chiyoko Kato, Eiji Sakashita, Kaoru Tominaga, Hitoshi Endo, Yoshinobu Kanda   +11 more
wiley   +1 more source